KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Recursion Pharmaceuticals (RXRX) Receivables - Net (2020 - 2022)

Recursion Pharmaceuticals (RXRX) has disclosed Receivables - Net for 3 consecutive years, with $21000.0 as the latest value for Q2 2022.

  • For the quarter ending Q2 2022, Receivables - Net fell 57.14% year-over-year to $21000.0, compared with a TTM value of $21000.0 through Jun 2022, down 57.14%, and an annual FY2021 reading of $34000.0, down 78.21% over the prior year.
  • Receivables - Net was $21000.0 for Q2 2022 at Recursion Pharmaceuticals, down from $34000.0 in the prior quarter.
  • Across five years, Receivables - Net topped out at $156000.0 in Q4 2020 and bottomed at $21000.0 in Q2 2022.
  • Average Receivables - Net over 3 years is $57000.0, with a median of $34000.0 recorded in 2021.
  • The sharpest move saw Receivables - Net crashed 78.21% in 2021, then tumbled 52.11% in 2022.
  • Year by year, Receivables - Net stood at $156000.0 in 2020, then plummeted by 78.21% to $34000.0 in 2021, then plummeted by 38.24% to $21000.0 in 2022.
  • Business Quant data shows Receivables - Net for RXRX at $21000.0 in Q2 2022, $34000.0 in Q1 2022, and $34000.0 in Q4 2021.